questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-tyrosine kinases
Protein-tyrosine kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Biopsie
Tests sanguins
Marqueurs tumoraux
Kinases
CA 19-9
Tests génétiques
Mutations
Kinases
Antécédents familiaux
Cancer
Kinases
Symptômes
5
Fatigue
Perte de poids
Kinases
Kinases
Voies de signalisation
Symptômes
Cancers
Masse palpable
Saignements
Fatigue
Maladies
Symptômes
Évolution des symptômes
Surveillance
Kinases
Prévention
5
Prévention
Alimentation saine
Exercice
Dépistage
Anomalies
Kinases
Vaccins
Prévention
Kinases
Tabagisme
Facteurs de risque
Kinases
Facteurs environnementaux
Substances chimiques
Kinases
Traitements
5
Inhibiteurs de kinases
Imatinib
Traitements
Traitements personnalisés
Mutations
Kinases
Effets secondaires
Fatigue
Nausées
Radiothérapie
Traitements ciblés
Kinases
Efficacité des traitements
Rémission
Kinases
Complications
5
Complications
Résistance aux traitements
Progression de la maladie
Complications
Gestion
Kinases
Pronostic
Complications
Rémission
Type de cancer
Complications
Kinases
Traitements supplémentaires
Complications
Kinases
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Tabagisme
Mode de vie
Risque
Kinases
Infections
Virus d'Epstein-Barr
Risque
Facteurs génétiques
Mutations
Kinases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes",
"headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines et peptides de signalisation intracellulaire",
"url": "https://questionsmedicales.fr/mesh/D047908",
"about": {
"@type": "MedicalCondition",
"name": "Protéines et peptides de signalisation intracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D047908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agammaglobulinaemia tyrosine kinase",
"alternateName": "Agammaglobulinaemia Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D000077329",
"about": {
"@type": "MedicalCondition",
"name": "Agammaglobulinaemia tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000077329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Focal adhesion protein-tyrosine kinases",
"alternateName": "Focal Adhesion Protein-Tyrosine Kinases",
"url": "https://questionsmedicales.fr/mesh/D051416",
"about": {
"@type": "MedicalCondition",
"name": "Focal adhesion protein-tyrosine kinases",
"code": {
"@type": "MedicalCode",
"code": "D051416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.049"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinases",
"alternateName": "Janus Kinases",
"url": "https://questionsmedicales.fr/mesh/D053612",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D053612",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Janus kinase 1",
"alternateName": "Janus Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D053613",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D053613",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinase 3",
"alternateName": "Janus Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D053616",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D053616",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "TYK2 Kinase",
"alternateName": "TYK2 Kinase",
"url": "https://questionsmedicales.fr/mesh/D053634",
"about": {
"@type": "MedicalCondition",
"name": "TYK2 Kinase",
"code": {
"@type": "MedicalCode",
"code": "D053634",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase Kinases",
"alternateName": "Mitogen-Activated Protein Kinase Kinases",
"url": "https://questionsmedicales.fr/mesh/D020929",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase Kinases",
"code": {
"@type": "MedicalCode",
"code": "D020929",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 1",
"alternateName": "MAP Kinase Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D048369",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D048369",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 2",
"alternateName": "MAP Kinase Kinase 2",
"url": "https://questionsmedicales.fr/mesh/D048370",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 2",
"code": {
"@type": "MedicalCode",
"code": "D048370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 3",
"alternateName": "MAP Kinase Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D048371",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 4",
"alternateName": "MAP Kinase Kinase 4",
"url": "https://questionsmedicales.fr/mesh/D048670",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 4",
"code": {
"@type": "MedicalCode",
"code": "D048670",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 5",
"alternateName": "MAP Kinase Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D048671",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 5",
"code": {
"@type": "MedicalCode",
"code": "D048671",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 6",
"alternateName": "MAP Kinase Kinase 6",
"url": "https://questionsmedicales.fr/mesh/D048669",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 6",
"code": {
"@type": "MedicalCode",
"code": "D048669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 7",
"alternateName": "MAP Kinase Kinase 7",
"url": "https://questionsmedicales.fr/mesh/D048688",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 7",
"code": {
"@type": "MedicalCode",
"code": "D048688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syk kinase",
"alternateName": "Syk Kinase",
"url": "https://questionsmedicales.fr/mesh/D000072377",
"about": {
"@type": "MedicalCondition",
"name": "Syk kinase",
"code": {
"@type": "MedicalCode",
"code": "D000072377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "src-Family kinases",
"alternateName": "src-Family Kinases",
"url": "https://questionsmedicales.fr/mesh/D019061",
"about": {
"@type": "MedicalCondition",
"name": "src-Family kinases",
"code": {
"@type": "MedicalCode",
"code": "D019061",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "CSK tyrosine-protein kinase",
"alternateName": "CSK Tyrosine-Protein Kinase",
"url": "https://questionsmedicales.fr/mesh/D000081247",
"about": {
"@type": "MedicalCondition",
"name": "CSK tyrosine-protein kinase",
"code": {
"@type": "MedicalCode",
"code": "D000081247",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800.158"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "ZAP-70 Protein-tyrosine kinase",
"alternateName": "ZAP-70 Protein-Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D051746",
"about": {
"@type": "MedicalCondition",
"name": "ZAP-70 Protein-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D051746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases",
"alternateName": "Protein-Tyrosine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D011505",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Angela L Tyner",
"url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu."
}
},
{
"@type": "Person",
"name": "Eiji Kinoshita",
"url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Emiko Kinoshita-Kikuta",
"url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Tohru Koike",
"url": "https://questionsmedicales.fr/author/Tohru%20Koike",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Gongqin Sun",
"url": "https://questionsmedicales.fr/author/Gongqin%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Recurrent encephalopathy associated with pegylated beta-interferon treatment.",
"datePublished": "2023-01-31",
"url": "https://questionsmedicales.fr/article/36736021",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jneuroim.2023.578037"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.",
"datePublished": "2024-05-29",
"url": "https://questionsmedicales.fr/article/38811970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12931-024-02854-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis.",
"datePublished": "2023-05-30",
"url": "https://questionsmedicales.fr/article/37325639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1162796"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early spinal cord pseudoatrophy in interferon-beta-treated multiple sclerosis.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36318271",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15620"
}
},
{
"@type": "ScholarlyArticle",
"name": "ATF1 Restricts Human Herpesvirus 6A Replication via Beta Interferon Induction.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36154610",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/jvi.01264-22"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-tyrosine kinases",
"item": "https://questionsmedicales.fr/mesh/D011505"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protein-tyrosine kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protein-tyrosine kinases",
"description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protein-tyrosine kinases",
"description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protein-tyrosine kinases",
"description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protein-tyrosine kinases",
"description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protein-tyrosine kinases",
"description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protein-tyrosine kinases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon-beta#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une suractivité des kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de kinase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux cancers ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins préventifs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases à tyrosine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements sont courants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles des traitements supplémentaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 30/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
University of Massachusetts Chan Medical School, Worcester, United States. Electronic address: swati.jaiswal@umassmed.edu.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jtl2003@med.cornell.edu.
Publications dans "Protein-tyrosine kinases" :
A 62-year-old woman with a history of multiple sclerosis (MS) presented with recurrent episodes of confusion, dysarthria and gait difficulties. These episodes occurred about 3 days after administratio...
Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. T...
In Part 1, patients (N = 13) with stable COPD were randomised 4:1 to SNG001 or placebo once-daily for three days. In Part 2, patients (N = 109) with worsening symptoms and a positive respiratory viral...
In Part 1, SNG001 upregulated sputum interferon gene expression. In Part 2, there were minimal SNG001-placebo differences in the efficacy endpoints; however, whereas gene expression was initially upre...
Overall, SNG001 was well-tolerated in patients with COPD, and upregulated lung antiviral defences to accelerate viral clearance. These findings warrant further investigation in a larger study....
EU clinical trials register (2017-003679-75), 6 October 2017....
Multiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. ...
The objective of this study was to determine the changes in DNAm associated with INFβ use, using methylation arrays and statistical deconvolutions on two separate datasets (total n...
We show that IFNβ treatment in people with MS modifies the methylation profile of interferon response genes in a strong, targeted, and reproducible manner. Using these identified methylation differenc...
In conclusion, our study shows that IFNβ treatment is a potent and targeted epigenetic modifier in multiple sclerosis....
Brain pseudoatrophy has been shown to play a pivotal role in the interpretation of brain atrophy measures during the first year of disease-modifying therapy in multiple sclerosis. Whether pseudoatroph...
A total of 129 patients from a prospective longitudinal multicentric national cohort study for whom magnetic resonance imaging scans at baseline, 12 months, and 24 months were available were selected ...
Patients treated with interferon-beta demonstrated accelerated annual percentage brain volume and cervical cord area change in the first year after treatment initiation, whereas atrophy rates stabiliz...
These results suggest that pseudoatrophy occurs not only in the brain, but also in the spinal cord during the first year of interferon-beta treatment....
The stimulus-induced cAMP response element (CRE)-binding protein (CREB) family of transcription factors bind to CREs to regulate diverse cellular responses, including proliferation, survival, and diff...
Treatments with interferon-beta (IFNβ) - a cytokine with established antiviral effects - were initially considered for multiple sclerosis (MS), as epidemiological data pointed towards a viral etiologi...
Fingolimod has been shown to be more effective in reducing relapse rate and disability than injectable therapies in clinical trials. An increase in N-acetylaspartate (NAA) as measured by MR spectrosco...
Ninety-eight RRMS (52 on fingolimod, 46 on injectable therapies (27 on glatiramer acetate and 19 on interferon) were age and sex-matched to 51 HCs. RRMS patients underwent cognitive, fatigue, and ment...
Clinical parameters, MR-volumetric, and neurometabolic profiles showed no differences between treatment groups (p > .05). Compared to HCs, both RRMS cohorts showed volume changes in white matter (-...
While both treatment arms showed overall similar volumetric and neurometabolic profiles, longitudinal studies are warranted to clarify neurometabolic changes and associations with treatment efficacy....
The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was recentl...
We first sequenced the genes encoding the IFN α/β receptor of the patients, who participated in the INTEREST study (ClinicalTrials.gov Identifier: NCT02622724 , November 24, 2015) in which the patient...
We found a novel disease association of a SNP rs9984273, which is situated in the interferon α/β receptor subunit 2 (IFNAR2) gene in an area corresponding to a binding motif of the glucocorticoid rece...
The distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signaling and glucocorticoids....
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously be...
Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as t...
A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Chan...
Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight int...
Varicella-Zoster virus (VZV) causes varicella in primary infection of children and zoster during reactivation in adults. Type I interferon (IFN) signaling suppresses VZV growth, and stimulator of inte...